论文部分内容阅读
目的:研究通络平嗽汤联合孟鲁司特钠及硫酸沙丁胺醇气雾剂在咳嗽变异性哮喘患儿中的疗效。方法:选择2013年1月—2014年1月的患儿100例,将患者随机分为观察组和对照组,各50例。对照组采用孟鲁司特钠及硫酸沙丁胺醇气雾剂治疗,观察组采用通络平嗽汤联合孟鲁司特钠及硫酸沙丁胺醇气雾剂治疗。治疗前后分别测定两组患儿的肺功能改善情况,并在治疗后将两组患儿的复发情况分析对比。结果:治疗组的咳嗽缓解时间、咳嗽消失时间均明显低于对照组,差异具有统计学意义(P<0.05);两组之间的复发率差异无统计学意义(P>0.05)。两组患儿治疗后的FVC、FEV1、FEV1.0、PEF与治疗前差异显效,具有统计学意义(P<0.05)。所有患儿在接受治疗方案规定的治疗剂量和疗程中未出现严重不良反应,两组之间安全性比较无显著性差异(P>0.05)。结论:通络平嗽汤联合孟鲁司特钠及硫酸沙丁胺醇气雾剂在咳嗽变异性哮喘患儿中的效果显著,且安全可靠,可以在临床上推广使用。
Objective: To study the curative effect of Tongluo Pingle Decoction combined with montelukast sodium and salbutamol sulfate aerosol in children with cough variant asthma. Methods: A total of 100 children aged from January 2013 to January 2014 were selected and randomly divided into observation group (50 cases) and control group (50 cases). The control group was treated with montelukast sodium and salbutamol sulfate aerosol. The observation group was treated with Tongluo Pinghu Decoction combined with montelukast sodium and salbutamol sulfate aerosol. Before and after treatment were measured in two groups of children with pulmonary function improvement, and after treatment, the recurrence of the two groups were analyzed and compared. Results: The cough relieving time and cough disappearing time in the treatment group were significantly lower than those in the control group (P <0.05). There was no significant difference in recurrence rate between the two groups (P> 0.05). FVC, FEV1, FEV1.0 and PEF after treatment in both groups were significantly different from those before treatment, with statistical significance (P <0.05). All patients did not have serious adverse reactions at the dose and course of treatment prescribed by the treatment regimen, and there was no significant difference in safety between the two groups (P> 0.05). Conclusion: The effect of Tongluo Pingle Decoction combined with montelukast sodium and salbutamol sulfate aerosol in children with cough variant asthma is significant, safe, reliable and can be widely used clinically.